New drug combo aims to protect kidneys from scarring
NCT ID NCT07030894
Summary
This study is testing whether combining two existing medicines—budesonide and ambrisentan—can help people with IgA nephropathy, a kidney disease. Researchers want to see if this combination reduces protein in urine and slows the decline of kidney function over 36 weeks. The study will include 129 adults who have been diagnosed with IgA nephropathy and have significant protein in their urine.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Hospital of Jilin University
RECRUITINGChangchun, Jilin, 130021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.